Bausch + Lomb Ends BL1107 Glaucoma Program After Phase 2 Trial Misses Main Goal

July 11, 2026

Eli Lilly’s Weight Loss Drug Significantly Reduces Diabetes Risk in Long-Term Study

August 22, 2024

Pfizer agrees to a $4.9 billion upfront purchase of Metsera to strengthen obesity portfolio

September 24, 2025

Must Read

Argenx purchases Forte for $2.2 billion to enter the hands-on phase two-stage medication for vitiligo

July 27, 2026

What Pharma Leaders Are Prioritizing in 2026

July 27, 2026

Takeda’s Qdenga Makes History as First Vaccine to Get the Nod in India

July 26, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Sanofi Ends Amlitelimab Development in Atopic Dermatitis After Phase 3 Program Review

J&J’s Bispecific Combination Works Wonders on Myeloma Progression in Phase 3 Study

Due to poor phase 2 data, Agios declares goodbye to the sickle cell program

Novartis Lets Go of Phase 2 Radioligand Therapy Following Clinic Disappointment

Argenx purchases Forte for $2.2 billion to enter the hands-on phase two-stage medication for vitiligo

Tempus purchases a specialist in cancer genomics in a $1.5 billion deal: Personalis

Samsung Biologics Plans $1.8 Billion Acquisition of PolyPeptide

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

What Pharma Leaders Are Prioritizing in 2026

How RNA Therapeutics Are Expanding Beyond Rare Diseases

The Future of AI-Assisted Clinical Operations

The End of Siloed Drug Development

Tag: Organon

Warren Buffett pulls out of Biogen but bets on Organon

Editor Picks

Bausch + Lomb Ends BL1107 Glaucoma Program After Phase 2 Trial Misses Main Goal

Eli Lilly’s Weight Loss Drug Significantly Reduces Diabetes Risk in Long-Term Study

Pfizer agrees to a $4.9 billion upfront purchase of Metsera to strengthen obesity portfolio

Must Read

Argenx purchases Forte for $2.2 billion to enter the hands-on phase two-stage medication for vitiligo

What Pharma Leaders Are Prioritizing in 2026

Takeda’s Qdenga Makes History as First Vaccine to Get the Nod in India

Hot Topics

About Us

Follow Us